China To Set Up Drug Innovation Structure Within Three Years
This article was originally published in PharmAsia News
Executive Summary
At the recent New Drug Innovation and CRO Forum in China, Vice Chairman of the Standing Committee of the National People's Congress Sang Guo-Wei reported that China's pharmaceutical industry's strategy is moving from imitating generic drugs to innovating on generics. Sang, who is also an academic at Chinese Academy of Engineering, noted that China has the basic requirements for creating new drugs, including talent, technology, industry and economic fundamentals. To date, the country has 150 medicines under clinical trials and 2,000 medicines ready for the clinical phase. China's goal is to establish an innovation system by stages: innovation transition phase from 2008 - 2010, when the government will invest at least 6.6 billion yuan $960 million) to set up the infrastructure; closing the gap between China and developed countries from 2011 - 2015; and by 2020, attaining the level of the developed countries. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.